Indeed, Bongartz et al. found an excess cancer risk on anti-TNF-α therapy (OR, 3.29, 95% CI [1.13–9.08]), but they only investigated infliximab and adalimumab, and included fewer RCTs including these two drugs in comparison with our present work. This evidence concerns the gene TNF and cancer.